Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy

BACKGROUND: NR2F6 has been proposed as an alternative cancer immune checkpoint in the effector T cell compartment. However, a realistic assessment of the in vivo therapeutic potential of NR2F6 requires acute depletion. METHODS: Employing primary T cells isolated from Cas9-transgenic mice for electro...

Descripción completa

Detalles Bibliográficos
Autores principales: Klepsch, Victoria, Pommermayr, Maria, Humer, Dominik, Brigo, Natascha, Hermann-Kleiter, Natascha, Baier, Gottfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961368/
https://www.ncbi.nlm.nih.gov/pubmed/31937317
http://dx.doi.org/10.1186/s12964-019-0454-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961368/
https://www.ncbi.nlm.nih.gov/pubmed/31937317
http://dx.doi.org/10.1186/s12964-019-0454-z

Ejemplares similares